What are the current guideline-recommended management strategies for hypertension in patients with chronic kidney disease (CKD), both with diabetes mellitus (DM) and without diabetes?

Management of Hypertension in CKD with and without Diabetes

All adults with CKD and hypertension should be treated to a target systolic blood pressure <120 mmHg using standardized office measurement, with RAS inhibitors (ACEi or ARB) as first-line therapy for those with albuminuria, and SGLT2 inhibitors added for all patients with diabetes and eGFR ≥20 ml/min per 1.73 m², or for non-diabetics with significant albuminuria (ACR ≥200 mg/g) or heart failure. 1

Blood Pressure Target

Target SBP <120 mmHg when tolerated, using standardized office BP measurement 2. This is a 2B recommendation but represents the most current evidence-based target. Critical caveat: This target applies only to standardized office measurements—applying this to routine office measurements is potentially hazardous 2. For patients with very limited life expectancy or symptomatic postural hypotension, less intensive targets are reasonable 2.

Pharmacologic Management Algorithm

Step 1: RAS Inhibitors (ACEi or ARB)

For CKD WITHOUT Diabetes:

• Severely increased albuminuria (A3): Start RASi (1B recommendation) 1, 2
• Moderately increased albuminuria (A2): Start RASi (2C recommendation) 1, 2
• No albuminuria (A1): Consider RASi for specific indications like hypertension or heart failure 1

For CKD WITH Diabetes:

• Moderately-to-severely increased albuminuria (A2 or A3): Start RASi (1B recommendation) 1, 2
• No albuminuria: RASi may be reasonable 2

Critical RASi Management Points:

• Use highest approved tolerated dose—benefits were proven at these doses 1
• Monitor BP, creatinine, and potassium within 2-4 weeks of initiation or dose increase 1
• Continue therapy unless creatinine rises >30% within 4 weeks 1
• Continue even when eGFR falls below 30 ml/min per 1.73 m² 1
• Manage hyperkalemia with potassium-lowering measures rather than stopping RASi 1
• Only reduce/discontinue for: symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or uremic symptoms with eGFR <15 1

Never combine ACEi + ARB + direct renin inhibitor (1B recommendation against) 2

Step 2: SGLT2 Inhibitors

For CKD WITH Type 2 Diabetes:

• Mandatory for all patients with eGFR ≥20 ml/min per 1.73 m² (1A recommendation) 1
• Once started, continue even if eGFR falls below 20 unless not tolerated or dialysis initiated 1

For CKD WITHOUT Diabetes:

• eGFR ≥20 with ACR ≥200 mg/g OR heart failure: Start SGLT2i (1A recommendation) 1
• eGFR 20-45 with ACR <200 mg/g: Consider SGLT2i (2B recommendation) 1

SGLT2i Management:

• Withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 1
• Reversible eGFR decrease on initiation is not an indication to stop 1

Step 3: Nonsteroidal Mineralocorticoid Receptor Antagonists

For Type 2 Diabetes with CKD:

• Add nonsteroidal MRA if albuminuria >30 mg/g persists despite maximum tolerated RASi (2A recommendation) 1
• Requires: eGFR >25 ml/min per 1.73 m² and normal potassium 1
• Can be added to RASi + SGLT2i combination 1
• Most appropriate for high-risk patients with persistent albuminuria despite standard therapy 1

Step 4: Additional Antihypertensives

When BP target not achieved with above agents:

• Calcium channel blockers (dihydropyridine preferred)
• Thiazide or thiazide-like diuretics (selection guided by renal function)
• Traditional MRAs (spironolactone/eplerenone) effective for refractory hypertension but monitor closely for hyperkalemia, especially with low eGFR 2

Lifestyle Modifications

• Sodium restriction: <5 g sodium chloride per day (approximately <2 g sodium) 2

  • Exception: Not appropriate for sodium-wasting nephropathy 2
  • Caution with DASH diet or potassium-rich salt substitutes in advanced CKD (hyperkalemia risk) 2

• Physical activity: Moderate-intensity exercise ≥150 minutes per week cumulative, or to cardiovascular tolerance 2

  • Modify based on cardiorespiratory fitness, physical limitations, cognitive function, and fall risk 2

Monitoring Strategy

• Check BP, creatinine, and potassium 2-4 weeks after RASi initiation or dose changes 1
• SGLT2i does not require altered monitoring frequency 1
• Continue regular CKD monitoring per standard protocols

Key Differences: Diabetes vs. Non-Diabetes

The 2024 KDIGO guidelines create a clear distinction: diabetic CKD patients receive SGLT2i universally (1A), while non-diabetic patients require either significant albuminuria (ACR ≥200) or heart failure for the same strength recommendation 1. Both groups receive RASi for albuminuria, but the threshold is lower and recommendation stronger for diabetic patients (A2 or A3 with 1B strength vs. A3 with 1B and A2 with 2C for non-diabetics) 1.

The addition of nonsteroidal MRA is currently only recommended for type 2 diabetes with persistent albuminuria 1, representing an additional layer of cardiorenal protection not yet extended to non-diabetic CKD in the guidelines.